{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,13]],"date-time":"2026-10-13T13:17:03Z","timestamp":1791897423078,"version":"4.3.4"},"reference-count":22,"publisher":"Springer Science and Business Media LLC","issue":"2","license":[{"start":{"date-parts":[[2024,10,19]],"date-time":"2024-10-19T00:00:00Z","timestamp":1729296000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"},{"start":{"date-parts":[[2024,10,19]],"date-time":"2024-10-19T00:00:00Z","timestamp":1729296000000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Endocrine"],"abstract":"<jats:title>Abstract<\/jats:title>\n          <jats:sec>\n            <jats:title>Purpose<\/jats:title>\n            <jats:p>Mortality in pituitary adenomas (PAs) has been extensively compared to general population. However, direct comparisons between PA subtypes are scarce. We aimed to compare mortality in various subtypes of PA (acromegaly, Cushing\u2019s disease (CD), macroprolactinomas and non-functioning pituitary macroadenomas (MacroNFPA)), within a single referral center.<\/jats:p>\n          <\/jats:sec>\n          <jats:sec>\n            <jats:title>Methods<\/jats:title>\n            <jats:p>We retrospectively analyzed mortality and survival time in all 962 PAs admitted in our department between 2011 and 2023: acromegaly (<jats:italic>n<\/jats:italic>\u2009=\u2009306), CD (<jats:italic>n<\/jats:italic>\u2009=\u200969), macroprolactinoma (<jats:italic>n<\/jats:italic>\u2009=\u2009168) and MacroNFPA (<jats:italic>n<\/jats:italic>\u2009=\u2009419).<\/jats:p>\n          <\/jats:sec>\n          <jats:sec>\n            <jats:title>Results<\/jats:title>\n            <jats:p>Median follow-up was 10.2 (5.2, 15.2) years. The overall survival probability was 90.9% and 78.1% after 10 and 20 years respectively with age at diagnosis as the only significant predictor. There were no significant differences in survival probability between various PA subtypes in the whole cohort. In patients over 45 years of age at diagnosis there was a significant difference in survival probability between the four groups (<jats:italic>p<\/jats:italic>\u2009=\u20090.01) in the first 15 years of follow-up. In head-to-head comparisons CD had a significantly higher mortality risk than patients with acromegaly (HR 3.38 [CI 95% 1.07 to 10.60]) even after adjusting for age and sex.<\/jats:p>\n          <\/jats:sec>\n          <jats:sec>\n            <jats:title>Conclusion<\/jats:title>\n            <jats:p>Patients diagnosed with CD after 45 years of age have a significantly lower survival probability than other PA subtypes in the first 15 years of follow-up. All other PA subtypes had a similar survival probability after adjusting for age and sex. Due to advances in medical treatment of hormone secreting tumors, mortality in patients with PAs might increasingly depend more on tumor mass than on hormonal hypersecretion.<\/jats:p>\n          <\/jats:sec>","DOI":"10.1007\/s12020-024-04073-y","type":"journal-article","created":{"date-parts":[[2024,10,19]],"date-time":"2024-10-19T05:02:49Z","timestamp":1729314169000},"page":"782-787","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":4,"title":["Comparative mortality in pituitary adenomas subtypes: a tertiary referral center study"],"prefix":"10.1007","volume":"87","author":[{"given":"Iustin Daniel","family":"Toma","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-6439-3523","authenticated-orcid":false,"given":"Dan Alexandru","family":"Niculescu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Simona Andreea","family":"G\u0103loiu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Raluca Alexandra","family":"Trif\u0103nescu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"C\u0103t\u0103lina","family":"Poian\u0103","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2024,10,19]]},"reference":[{"key":"4073_CR1","doi-asserted-by":"publisher","first-page":"iv1","DOI":"10.1093\/neuonc\/nov189","volume":"17","author":"QT Ostrom","year":"2015","unstructured":"Q.T. Ostrom, H. Gittleman, J. Fulop, M. Liu, R. Blanda et al. CBTRUS statistical report: Primary brain and central nervous system tumors diagnosed in the United States in 2008\u20132012. Neuro Oncol. 17, iv1\u2013iv62 (2015)","journal-title":"Neuro Oncol."},{"key":"4073_CR2","first-page":"205","volume":"12","author":"RT Costello","year":"1936","unstructured":"R.T. Costello, Subclinical adenoma of the pituitary gland. Am. J. Pathol. 12, 205\u2013216.1 (1936)","journal-title":"Am. J. Pathol."},{"key":"4073_CR3","doi-asserted-by":"publisher","first-page":"613","DOI":"10.1002\/cncr.20412","volume":"101","author":"S Ezzat","year":"2004","unstructured":"S. Ezzat, S.L. Asa, W.T. Couldwell, C.E. Barr, W.E. Dodge et al. The prevalence of pituitary adenomas: a systematic review. Cancer 101, 613\u2013619 (2004)","journal-title":"Cancer"},{"key":"4073_CR4","doi-asserted-by":"publisher","first-page":"655","DOI":"10.1530\/EJE-15-0189","volume":"173","author":"TT Agustsson","year":"2015","unstructured":"T.T. Agustsson, T. Baldvinsdottir, J.G. Jonasson, E. Olafsdottir, V. Steinthorsdottir et al. The epidemiology of pituitary adenomas in Iceland, 1955\u20132012: a nationwide population-based study. Eur. J. Endocrinol. 173, 655\u2013664 (2015)","journal-title":"Eur. J. Endocrinol."},{"key":"4073_CR5","doi-asserted-by":"publisher","first-page":"59","DOI":"10.1530\/EJE-18-0255","volume":"179","author":"F Bolfi","year":"2018","unstructured":"F. Bolfi, A.F. Neves, C.L. Boguszewski, V.S. Nunes-Nogueira, Mortality in acromegaly decreased in the last decade: a systematic review and meta-analysis. Eur. J. Endocrinol. 179, 59\u201371 (2018)","journal-title":"Eur. J. Endocrinol."},{"issue":"4","key":"4073_CR6","doi-asserted-by":"publisher","first-page":"691","DOI":"10.1007\/s11154-024-09875-z","volume":"25","author":"C Rosendal","year":"2024","unstructured":"C. Rosendal, M.C. Arlien-S\u00f8borg, E.H. Nielsen, M.S. Andersen, C.L. Feltoft et al. The changing landscape of acromegaly - an epidemiological perspective. Rev. Endocr. Metab. Disord. 25(4), 691\u2013705 (2024)","journal-title":"Rev. Endocr. Metab. Disord."},{"key":"4073_CR7","doi-asserted-by":"publisher","first-page":"2193","DOI":"10.1210\/clinem\/dgad141","volume":"108","author":"B Biagetti","year":"2023","unstructured":"B. Biagetti, P. Iglesias, R. Villar-Taibo, M.-D. Moure, M. Paja et al. Mortality in acromegaly diagnosed in older individuals in spain is higher in women compared to the general Spanish population. J. Clin. Endocrinol. Metab. 108, 2193\u20132202 (2023)","journal-title":"J. Clin. Endocrinol. Metab."},{"key":"4073_CR8","doi-asserted-by":"publisher","first-page":"225","DOI":"10.1093\/ejendo\/lvad106","volume":"189","author":"J Kim","year":"2023","unstructured":"J. Kim, N. Hong, J. Choi, J.H. Moon, E.H. Kim et al. Sex differences in mortality in patients with acromegaly: a nationwide cohort study in Korea. Eur. J. Endocrinol. 189, 225\u2013234 (2023)","journal-title":"Eur. J. Endocrinol."},{"key":"4073_CR9","doi-asserted-by":"publisher","first-page":"551","DOI":"10.1007\/s11102-023-01343-2","volume":"26","author":"A Mondin","year":"2023","unstructured":"A. Mondin, F. Ceccato, G. Voltan, P. Mazzeo, R. Manara et al. Complications and mortality of Cushing\u2019s disease: report on data collected over a 20-year period at a referral centre. Pituitary 26, 551\u2013560 (2023)","journal-title":"Pituitary"},{"key":"4073_CR10","doi-asserted-by":"publisher","first-page":"38","DOI":"10.1007\/s11102-020-01084-6","volume":"24","author":"JS Oh","year":"2021","unstructured":"J.S. Oh, H.J. Kim, H.J. Hann, T.U. Kang, D.S. Kim et al. Incidence, mortality, and cardiovascular diseases in pituitary adenoma in Korea: a nationwide population-based study. Pituitary 24, 38\u201347 (2021)","journal-title":"Pituitary"},{"issue":"9","key":"4073_CR11","doi-asserted-by":"publisher","first-page":"2143","DOI":"10.1007\/s40618-024-02356-9","volume":"47","author":"F Bioletto","year":"2024","unstructured":"F. Bioletto, M. Sibilla, V. Gasco, E. Ghigo, S. Grottoli, Excess mortality in patients with non-functioning pituitary adenoma: a systematic review and meta-analysis. J. Endocrinol. Invest 47(9), 2143\u20132155 (2024)","journal-title":"J. Endocrinol. Invest"},{"key":"4073_CR12","doi-asserted-by":"publisher","first-page":"329","DOI":"10.1530\/EJE-21-0729","volume":"186","author":"S Arnard\u00f3ttir","year":"2022","unstructured":"S. Arnard\u00f3ttir, J. J\u00e4r\u00e5s, P. Burman, K. Berinder, P. Dahlqvist et al. Long-term outcomes of patients with acromegaly: a report from the Swedish Pituitary Register. Eur. J. Endocrinol. 186, 329\u2013339 (2022)","journal-title":"Eur. J. Endocrinol."},{"key":"4073_CR13","doi-asserted-by":"publisher","first-page":"476","DOI":"10.4183\/aeb.2015.476","volume":"11","author":"S Galoiu","year":"2015","unstructured":"S. Galoiu, A. \u0218uvoial\u0103, M. Purice, A. Caragheorgheopol, A. Dumitra\u0219cu et al. Mortality of patients with acromegaly FROM a tertiary national neuroendocrine center. Acta Endocrinologica (Buchar.) 11, 476\u2013481 (2015)","journal-title":"Acta Endocrinologica (Buchar.)"},{"key":"4073_CR14","first-page":"235","volume":"71","author":"MC Marinescu","year":"2020","unstructured":"M.C. Marinescu, I. Baciu, N. Baculescu, C.A.-M. Capatina, R. Dusceac et al. Improvement of acromegaly control with multimodal therapy in Romania. Endokrynol. Pol. 71, 235\u2013239 (2020)","journal-title":"Endokrynol. Pol."},{"key":"4073_CR15","doi-asserted-by":"publisher","first-page":"2651","DOI":"10.1210\/jc.2015-1475","volume":"100","author":"DS Olsson","year":"2015","unstructured":"D.S. Olsson, A.G. Nilsson, I.-L. Bryngelsson, P. Trimpou, G. Johannsson et al. Excess mortality in women and young adults with nonfunctioning pituitary adenoma: A Swedish nationwide study. J. Clin. Endocrinol. Metab. 100, 2651\u20132658 (2015)","journal-title":"J. Clin. Endocrinol. Metab."},{"key":"4073_CR16","doi-asserted-by":"publisher","first-page":"144","DOI":"10.1007\/s11102-022-01292-2","volume":"26","author":"A Akirov","year":"2023","unstructured":"A. Akirov, L. Dery, M. Fleseriu, Y. Rudman, I. Shimon et al. Cushing\u2019s syndrome in women: age-related differences in etiology and clinical picture. Pituitary 26, 144\u2013151 (2023)","journal-title":"Pituitary"},{"key":"4073_CR17","doi-asserted-by":"publisher","first-page":"2518","DOI":"10.1210\/jcem.84.7.5810","volume":"84","author":"J Verhelst","year":"1999","unstructured":"J. Verhelst, R. Abs, D. Maiter, A. van den Bruel, M. Vandeweghe et al. Cabergoline in the treatment of hyperprolactinemia: a study in 455 patients. J. Clin. Endocrinol. Metab. 84, 2518\u20132522 (1999)","journal-title":"J. Clin. Endocrinol. Metab."},{"key":"4073_CR18","first-page":"316","volume":"41","author":"A Tirosh","year":"2016","unstructured":"A. Tirosh, I. Shimon, Current approach to treatments for prolactinomas. Minerva Endocrinol. 41, 316\u2013323 (2016)","journal-title":"Minerva Endocrinol."},{"key":"4073_CR19","doi-asserted-by":"publisher","DOI":"10.1038\/s41598-021-94658-8","volume":"11","author":"C Chen","year":"2021","unstructured":"C. Chen, Y. Hu, L. Lyu, S. Yin, Y. Yu et al. Incidence, demographics, and survival of patients with primary pituitary tumors: a SEER database study in 2004\u20132016. Sci. Rep. 11, 15155 (2021)","journal-title":"Sci. Rep."},{"key":"4073_CR20","doi-asserted-by":"publisher","DOI":"10.3389\/fendo.2024.1348972","volume":"15","author":"S G\u0103loiu","year":"2024","unstructured":"S. G\u0103loiu, I.-D. Toma, D.I. T\u0103nasie, A. B\u0103rbulescu, I. Baciu et al. High mortality risk among women with acromegaly still persists. Front Endocrinol. (Lausanne) 15, 1348972 (2024)","journal-title":"Front Endocrinol. (Lausanne)"},{"key":"4073_CR21","doi-asserted-by":"publisher","first-page":"203","DOI":"10.1007\/s11102-018-0863-9","volume":"21","author":"M Tampourlou","year":"2018","unstructured":"M. Tampourlou, A. Fountas, G. Ntali, N. Karavitaki, Mortality in patients with non-functioning pituitary adenoma. Pituitary 21, 203\u2013207 (2018)","journal-title":"Pituitary"},{"key":"4073_CR22","doi-asserted-by":"publisher","first-page":"3003","DOI":"10.1007\/s00701-023-05772-7","volume":"165","author":"CM Falch","year":"2023","unstructured":"C.M. Falch, A.K. Dupont, N.C. Olarescu, M. Wiedmann, D. Dahlberg et al. Long-term control of acromegaly after pituitary surgery in South-Eastern Norway. Acta Neurochir. (Wien.) 165, 3003\u20133010 (2023)","journal-title":"Acta Neurochir. (Wien.)"}],"container-title":["Endocrine"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s12020-024-04073-y.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s12020-024-04073-y\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s12020-024-04073-y.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,2,10]],"date-time":"2025-02-10T12:28:22Z","timestamp":1739190502000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s12020-024-04073-y"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2024,10,19]]},"references-count":22,"journal-issue":{"issue":"2","published-online":{"date-parts":[[2025,2]]}},"alternative-id":["4073"],"URL":"https:\/\/doi.org\/10.1007\/s12020-024-04073-y","relation":{},"ISSN":["1559-0100"],"issn-type":[{"value":"1559-0100","type":"electronic"}],"subject":[],"published":{"date-parts":[[2024,10,19]]},"assertion":[{"value":"7 July 2024","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"9 October 2024","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"19 October 2024","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Compliance with ethical standards"}},{"value":"The authors declare no competing interests.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Conflict of interest"}},{"value":"The study was approved by the C. I. Parhon National Institute of Endocrinology Ethics Committee (No 9\/09.02.2023).","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethical approval"}}]}}